Product Information
QELBREE ER 200 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $12.7421 per EA under NDC 17772013360. Its NADAC has been published 198 times since Sep 14, 2022.
Strength
200 mg/1
Manufacturer
Supernus Pharmaceuticals Inc.NDC
17772013360
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
VILOXAZINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA211964On Market Since
4/2/2021
Pharmacological Classes
Price Statistics
The NADAC for QELBREE ER 200 MG CAPSULE has been published 198 times since Sep 14, 2022, and over the history we have for it it has risen 26.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.7421 per EA |
|---|---|
| All-time high | $12.7551 (May 13, 2026) |
| All-time low | $10.1043 (Sep 14, 2022) |
| 52-week high | $12.7551 |
| 52-week low | $12.0331 |
| Median price | $11.3713 |
| Average price | $11.4546 |
| Largest weekly change | +6.0% (Jan 3, 2024) |
| Weeks tracked | 198 |
| Tracking since | Sep 14, 2022 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of QELBREE ER 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for QELBREE ER 200 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $12.7421 per EA (NDC 17772013360), effective Jun 24, 2026.
How has the price of QELBREE ER 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for QELBREE ER 200 MG CAPSULE has risen 26.1%. It has been tracked across 198 weekly CMS publications since Sep 14, 2022.
What are the highest and lowest recorded NADAC prices for QELBREE ER 200 MG CAPSULE?
Since Sep 14, 2022, the NADAC for QELBREE ER 200 MG CAPSULE has ranged from a low of $10.1043 (Sep 14, 2022) to a high of $12.7551 (May 13, 2026), with a median of $11.3713 per EA.
Are there cheaper alternatives to QELBREE ER 200 MG CAPSULE?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as QELBREE ER 200 MG CAPSULE, but none are currently priced below it.
Who manufactures QELBREE ER 200 MG CAPSULE?
QELBREE ER 200 MG CAPSULE (NDC 17772013360) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification